Hallym University Sacred Heart Hospital, 'Hallym International Antibiotic Resistance Center'Opening'Global Hub Leap'
Nov 13, 2024
|
More than 80 domestic and foreign guests attended the opening ceremony, including Eva Tiensu Jansson, vice president of Sweden's Uppsala University, Dan Andersson, head of the Uppsala Antibiotic Center, Yoon Hee-sung, chairman of the school corporation Ilsong Academy, Kim Yong-sun, head of Hallym University Medical Center, Yoo Kyung-ho, head of Hallym University's College of Medicine, and Kim Hyung-soo, head of Hallym University's Sacred Heart Hospital.
The Hallym International Antibiotic Resistance Center is a multidisciplinary convergence research center composed of professors in various fields such as infectious medicine, cardiovascular thoracic surgery, respiratory medicine, diagnostic laboratory medicine, clinical pharmacology, and microbiology, and the Department of Artificial Intelligence Convergence at Hallym University. In the future, research will be conducted with the aim of solving antibiotic resistance problems at home and abroad through precision antibiotic treatment research, pathogen bio big data establishment, and international antibiotic resistance research network.
Hallym University Sacred Heart Hospital plans to strengthen cooperation in research on antibiotic resistance and precision antibiotic treatment at home and abroad to become a joint research hub for global antibiotic resistance. Based on the nation's best digital healthcare technology owned by Hallym University Medical Center and its network of five hospitals, it plans to expand antibiotic resistance research worldwide by promoting joint research with leading overseas research institutes.
Since February this year, Hallym University Sacred Heart Hospital has already been conducting research on the world's first rapid diagnosis tool for combined personalized antibiotic treatment (product name: CombiANT, Combiant) with Sweden's Uppsala Antibiotic Center (UAC), a global antibiotic research institute, and Seoul Asan Hospital.
Multidrug-resistant bacterial infections are currently emerging as a medical challenge that must be solved worldwide. Multidrug-resistant bacteria are bacteria that are resistant to several types of antibiotics, and few or only some can treat them, requiring personalized customized treatment or combined treatment prescribing one or more antibiotics. However, when combined with different antibiotics, there is no internationally standardized prescription standard and treatment without considering interactions between antibiotics can be less effective.
This joint study combines the big data system owned by Hallym University Medical Center with the hospital network, the technology possessed by Uppsala Antibiotic Center, and the research power of Asan Medical Center in Seoul to solve these problems and produce better treatment results.
Combiant can quickly find out which combination of antibiotics can have a synergistic effect on treatment, enabling personalized antibiotic treatment. In addition, the use of only necessary antibiotics can prevent side effects from misuse.
In addition, the Hallym International Antibiotic Resistance Center plans to establish a network with world-class authorities in the field of antibiotic resistance and promote joint research.
Kim Yong-kyun, director of the Hallym International Antibiotic Resistance Center, will present a research presentation at the '2024 BrainLink Technology Exchange Conference: Joint Research New Initiative on Global Antibiotic Resistance' to be held in Busan from November 13 to 15.
BrainLink is an excellent researcher exchange support project operated by the Korea Research Foundation of the Ministry of Science and ICT with the aim of establishing an international research network between overseas scholars and domestic researchers. A large number of domestic and foreign scholars will participate in this BrainLink technology exchange. Forty-seven antibiotic resistance experts from five countries, including Professor Vance G. Fowler of Duke University in the United States, Professor Victor Nizet of the University of California, San Diego, Professor Dan Andersson of the University of Uppsala, Sweden, and Professor Kim Yang-soo of Asan Medical Center in Seoul, will be present.
On this day, center director Kim will present an international joint study on the combined treatment of personalized antibiotics for methicillin-resistant Staphylococcus aureus bacteremia, which is being jointly studied by the Hallim International Antibiotic Resistance Center, Uppsala University, and Seoul Asan Hospital.
According to the study, treatment of methicillin-resistant Staphylococcus aureus bacteremia, which has a 30% mortality rate worldwide, can not only shorten the duration of bacteremia but also reduce the mortality rate.
Kim Yong-kyun, director of the center, plans to share the research results through the presentation and lay the foundation for a joint research network with world-class infectious diseases experts.
Meanwhile, the World Health Organization (WHO) has named antibiotic resistance as one of '10 risks threatening human survival'. The United Nations Environment Program (UNEP) analyzed that more than 5 million people die annually worldwide from antibiotic-resistant bacteria, and the number will increase to 10 million by 2050. In Korea, the number of patients with super bacteria infection reached 40,000 last year, the largest ever.
Hallim University Sacred Heart Hospital was designated by the Korea Centers for Disease Control and Prevention as a medical-related infectious bacteria pathogen resource bank in January of this year and is leading the state-led research on antibiotic resistance bacteria. In particular, it is focusing on researching antibiotic resistance using digital technology, such as developing an optimal antibiotic dose recommendation algorithm and an antibiotic-resistant bacteria prediction model based on artificial intelligence (AI) as well as personalized antibiotic treatment.
|
bellho@sportschosun.com
